Trump Directs FDA Review of Psychedelics as Breakthrough Therapies
President Donald Trump signed an executive order in the Oval Office on Saturday, April 18, 2026. The move aims to speed federal review of certain psychedelic therapies.
Order directs faster FDA review
The order instructs the Food and Drug Administration to expedite reviews. It targets psychedelics already labeled as breakthrough therapy drugs.
Administration officials described the change as a way to shorten approval timelines. The president framed it as a patient-access measure.
Policy goals and clinical context
Trump said the directive would enact historic reforms to accelerate access to new medical research. The reforms focus on treatments derived from psychedelic compounds.
He noted many of these therapies are in advanced clinical trials. Those trials aim to confirm safety and efficacy for American patients.
Mental health emphasis and veterans
The president highlighted early data suggesting life-changing effects for severe mental illness. He specifically mentioned benefits for patients with depression.
Trump also cited concerns about the veteran suicide rate. He portrayed faster approval as particularly important for veterans seeking new treatments.
Context and coverage
The announcement was captured in photographs by Julia Demaree Nikhinson/AP inside the White House. The signing took place in Washington, D.C.
Reporting for Filmogaz.com by Greg Norman noted the administration’s language and timeline. This is a developing story, and updates may follow.
Key phrase: Trump Directs FDA Review of Psychedelics as Breakthrough Therapies.
